

# Yunpeng Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7011044/publications.pdf>

Version: 2024-02-01

19  
papers

764  
citations

840776

11  
h-index

794594

19  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1351  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 3097-3107.        | 7.0  | 357       |
| 2  | M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 6125-6138.  | 1.9  | 96        |
| 3  | Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cells. <i>Molecular Cancer</i> , 2014, 13, 136.                       | 19.2 | 74        |
| 4  | Long non-coding RNA UCA1 upregulation promotes the migration of hypoxia-resistant gastric cancer cells through the miR-7-5p/EGFR axis. <i>Experimental Cell Research</i> , 2018, 368, 194-201.                 | 2.6  | 49        |
| 5  | NPTX1 promotes metastasis via integrin/FAK signaling in gastric cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 3237-3251.  | 1.9  | 34        |
| 6  | Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis bearing acquired EGFR L718Q mutation: a case report. <i>BMC Cancer</i> , 2019, 19, 702. | 2.6  | 27        |
| 7  | N6-Methyladenosine RNA Demethylase FTO Promotes Gastric Cancer Metastasis by Down-Regulating the m6A Methylation of ITGB1. <i>Frontiers in Oncology</i> , 2021, 11, 681280.                                    | 2.8  | 26        |
| 8  | Nuclear PD-L1 promotes cell cycle progression of BRAF-mutated colorectal cancer by inhibiting THRAP3. <i>Cancer Letters</i> , 2022, 527, 127-139.  | 7.2  | 18        |
| 9  | ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage. <i>Cell Cycle</i> , 2018, 17, 595-604.                                  | 2.6  | 14        |
| 10 | AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status. <i>British Journal of Cancer</i> , 2018, 118, 1453-1463.                             | 6.4  | 13        |
| 11 | Identification of Subtype-Specific Three-Gene Signature for Prognostic Prediction in Diffuse Type Gastric Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1243.  | 2.8  | 13        |
| 12 | Comprehensive analysis of genes based on chr1p/19q co-deletion reveals a robust 4-gene prognostic signature for lower grade glioma. <i>Cancer Management and Research</i> , 2019, Volume 11, 4971-4984.        | 1.9  | 9         |
| 13 | Comparative Analysis and in vitro Experiments of Signatures and Prognostic Value of Immune Checkpoint Genes in Colorectal Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3517-3534.                 | 2.0  | 8         |
| 14 | Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 1963-1970.                       | 4.3  | 7         |
| 15 | Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer. <i>Cancer Management and Research</i> , 2020, Volume 12, 4029-4038.                     | 1.9  | 7         |
| 16 | DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53-deficient pancreatic cancer cells. <i>Molecular Medicine Reports</i> , 2018, 17, 117-124.           | 2.4  | 4         |
| 17 | PD-L1 upregulation accompanied with epithelial-mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells. <i>Medical Oncology</i> , 2020, 37, 47.                  | 2.5  | 4         |
| 18 | RAS Mutational Status Detection in Tissue, Plasma, and Stool Samples for Colorectal Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-6.  | 1.9  | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Complete Pathologic Response of Multiple Liver Metastases and Clinical Complete Response of Rectal Cancer in a Patient with Ataxia-Telangiectasia Mutated Gene Mutations After XELOXIRI Plus Bevacizumab: A Case Report. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4201-4209. | 2.0 | 2         |